DRUG
DDAVP
Patients Receiving DDAVP prior to operation
Status
Terminated
Phase
Phase 2
Enrollment
14
Locations
1
Results
Posted
Publications
0
Study summary
This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets that promote clotting. In the study, participants who are have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive medication. Photographs taken before and shortly after surgery will be evaluated for the amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are not eligible to participate.
Interventions
DRUG
Patients Receiving DDAVP prior to operation
Timeline
First posted
Nov 13, 2013
Study start
Dec 2013
Primary completion
Jun 25, 2015
Study completion
Jun 25, 2015
Results posted
Aug 16, 2023
Registry updated
Aug 16, 2023
Outcomes
Reduction in Ecchymosis and Swelling
Time frame · surgery to 8 days post-operatively
Photographs taken preoperatively at 1 day and 8 days post-operatively will be analyzed for bruising
Patient Behavior Factors
Time frame · Surgery to 3 weeks post-operatively
Looking at the time it takes for patients to feel comfortable wearing makeup, going out in public, and returning to work
Eligibility
Inclusion Criteria: * Undergoing Rhinoplasty where nasal bone osteotomy is necessary Exclusion Criteria: * Heart Disease * Renal Disease with decreased GFR * Liver Disease
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Lyndhurst Surgery Center
Lyndhurst, Ohio, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.